[Antidote treatment during use of direct anticoagulants]

Tidsskr Nor Laegeforen. 2018 Feb 5;138(3). doi: 10.4045/tidsskr.17.0190. Print 2018 Feb 6.
[Article in Norwegian]
No abstract available

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticoagulants / adverse effects*
  • Antidotes / therapeutic use*
  • Dabigatran / adverse effects
  • Dabigatran / antagonists & inhibitors
  • Female
  • Hemorrhage* / chemically induced
  • Hemorrhage* / drug therapy
  • Hemorrhage* / prevention & control
  • Humans
  • Male
  • Pyrazoles / adverse effects
  • Pyrazoles / antagonists & inhibitors
  • Pyridines / adverse effects
  • Pyridines / antagonists & inhibitors
  • Pyridones / adverse effects
  • Pyridones / antagonists & inhibitors
  • Risk
  • Rivaroxaban / adverse effects
  • Rivaroxaban / antagonists & inhibitors
  • Thiazoles / adverse effects
  • Thiazoles / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antidotes
  • Pyrazoles
  • Pyridines
  • Pyridones
  • Thiazoles
  • apixaban
  • idarucizumab
  • Rivaroxaban
  • Dabigatran
  • edoxaban